Are you interested in exploring collaboration possibilities?
Enter your information in the form and a representative will contact you shortly.
C1SIG Is a Risk Predictor for All-Cause Mortality at Admission With STEMI
September 24, 2024
Introduction
ST-elevated myocardial infarction (STEMI) damages local cardiac tissue and leads to acute inflammation-driven tissue remodelling immediately after injury. A collagen type I (COL1) matricryptin cleaved
by MMP-2 and MMP-9 was previously identified as being involved in left ventricular remodelling after a MI. We aimed to develop, technically evaluate, and quantify this COL1- derived matricryptin, named C1SIG, as a serological biomarker in a clinical cohort of STEMI patients.
Poster
Conclusion
C1SIG was developed as a technically robust biomarker and demonstrated as an independent predictor of
mortality at 30 days and 1-year after STEMI, even when adjusted for multiple clinically-relevant variables.
This COL1 biomarker could be helpful in assessing acute extracellular matrix processing in individuals after suffering a STEMI and could identify a subset of patients at increased risk of long-term outcome.
